NCRI 2016 | Cancer cachexia and novel targeted therapies

David Currow, PhD, MPH, FRACP, FAChPM, FAHMS, GAICD of Flinders University, Adelaide, Australia discusses cancer cachexia and novel targeted therapies for its treatment at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK. Prof. Currow explains that there have been no options for treatment so far. There are, however, Phase III studies of novel agents including a ghrelin agonist, that are demonstrating effects on cachexia as he discusses. This suggests that there are possibilities for treatment.